Clinical Trials Logo

Rectal Neoplasms clinical trials

View clinical trials related to Rectal Neoplasms.

Filter by:

NCT ID: NCT04150705 Terminated - Rectal Cancer Clinical Trials

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The goal of pilot study is to assess the feasibility of FDG-PET/MRI for monitoring rectal cancer disease status in the setting of rectal cancer non-operative management (NOM). Data from this study will be used to guide the design of future clinical trials involving FDG-PET/MRI for rectal cancer NOM.

NCT ID: NCT04147481 Enrolling by invitation - Gastric Cancer Clinical Trials

Effects of Abdominal Nerve Block on Postoperative Recovery in Patients Undergoing Gastrointestinal Surgery

Start date: October 21, 2019
Phase: N/A
Study type: Interventional

To explore the effect of general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) on the recovery of patients with gastrointestinal tumor after surgical treatment.

NCT ID: NCT04141566 Completed - Quality of Life Clinical Trials

Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal Adenocarcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

Aim of this study is to compare the cost-effectiveness and the quality of life in the 6 months following the surgery of a pseudo continent perineal colostomy (PCPC) and a permanent left iliac colostomy (PLIC) following an abdominoperineal resection (APR) for ultra low rectal cancer

NCT ID: NCT04139967 Terminated - Cancer, Rectal Clinical Trials

Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

This study will help determine if a short course of radiation therapy is effective to treat rectal cancer in older patients. A shorter course of radiation treatment may be better tolerated than a longer course or surgery for the treatment of rectal cancer in the elderly.

NCT ID: NCT04135313 Enrolling by invitation - Rectal Cancer Clinical Trials

Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer

RuCorT-03
Start date: October 20, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the addition of 2 cycles of induction CapOx chemotherapy and 2 cycles of consolidation CapOx chemotherapy to standard chemoradiation improves 3-year disease-free survival in patients with locally advanced CRM"+" mid and low rectal cancer.

NCT ID: NCT04134897 Enrolling by invitation - Rectal Cancer Clinical Trials

Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer

RuCorT-02
Start date: October 14, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM"-" mid rectal cancer.

NCT ID: NCT04130854 Active, not recruiting - Clinical trials for Locally Advanced Rectal Adenocarcinoma

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Start date: April 24, 2020
Phase: Phase 2
Study type: Interventional

Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.

NCT ID: NCT04128657 Completed - Clinical trials for Rectal Cancer Patients

Validation of the Moroccan Arabic Version of the Low Anterior Resection Syndrome (LARS) and Wexner Score of Continence Among Rectal Cancer Patients

MA_LARSWEX
Start date: January 1, 2019
Phase:
Study type: Observational

In the past decade, colorectal cancer management improved considerably with total mesorectal excision as well as the multidisciplinary management relying on neoadjuvant radiochemotherapy. This forward leap is currently responsible for an increase in the survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the surgical approach is now more inclined towards sphincter preserving procedures, which allows the conservation of body image but can have negative bowel function repercussions consisting of urgency and incontinence ; all these terms encompassed in the low anterior resection syndrome. In the light of these findings many studies developed assessment tools in order to objectively measure this functional alteration among which are the low anterior resection syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel function after sphincter-preserving surgery are now translated and validated into various languages and used in different countries. The LARS score relies on the frequency of the symptoms and allows the categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score relies on the examination of the frequency of three types of fecal incontinence (solid, liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency options ranging from never (score 0) through to always (meaning at least once per day; score 4). The score ranges from 0 (perfect continence) to 20 (complete incontinence). The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan arabic dialect.

NCT ID: NCT04127734 Not yet recruiting - Rectal Cancer Clinical Trials

Treatment of Anastomotic Leakage After Rectal Cancer Resection

TENTACLE:R
Start date: April 1, 2020
Phase:
Study type: Observational

The TENTACLE: Rectum study is a multinational retrospective cohort study that includes patients with anastomotic leakage after rectal cancer resection. The study aims to develop an anastomotic leakage severity score and to evaluate the efficacy of different treatments of anastomotic leakage.

NCT ID: NCT04124601 Completed - Rectal Cancer Clinical Trials

Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

CHINOREC
Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.